David Lazar

David Elliot Lazar assumed the role of CEO and Executive Director at Quantum Cyber N.V. in 2026, taking the helm of a Nasdaq-listed company assembling an AI-powered, quantum-accelerated System-of-Systems autonomous defense platform. Under his leadership, Quantum Cyber has secured exclusive intellectual property rights to autonomous drone systems from BP United and is establishing a U.S.-based defense-technology manufacturing complex. Lazar has personally invested approximately $6 million in the company through preferred share purchases.

Lazar serves as CEO and Managing Member of Activist Investing LLC, an investment vehicle he has operated since March 2018 to identify turnaround opportunities in distressed public companies. He also served as CEO of Custodian Ventures LLC since February 2018, which specializes in assisting distressed public companies through custodianship. Prior to founding these firms, Lazar was Managing Partner at Zenith Partners International Inc., a boutique consulting firm, from 2012 to 2018.

Career history

• CEO and Executive Director, Quantum Cyber N.V. (2026–present)
• Chief Executive Officer and Director, NovaBay Pharmaceuticals (2025–present)
• Interim CEO and CFO, Cyclacel Pharmaceuticals, a biopharmaceutical company developing cancer medicines
• President, OpGen, a precision medicine company focused on molecular diagnostics to combat infectious disease
• CEO, Minim, a telecommunications equipment company delivering smart software-driven communications products
• CEO, Custodian Ventures LLC (2018–present)
• CEO, Activist Investing LLC (2018–present)
• Managing Partner, Zenith Partners International Inc. (2012–2018)

Lazar brings expertise in financial and legal management, public company operations, SEC regulations, capital restructuring, debt financing, and mergers and acquisitions. What David E. Lazar could bring to Quantum Cyber N.V.: His documented track record in activist investing and distressed-company restructuring positions him to navigate the regulatory and capital requirements of defense technology commercialization. His history of multiple CEO roles across pharmaceutical and telecommunications companies demonstrates executive agility across complex technical sectors, while his personal $6 million investment signals alignment with shareholder interests in scaling the autonomous defense platform.